Masimo Co. (NASDAQ:MASI) Expected to Post Quarterly Sales of $295.72 Million

Wall Street brokerages expect Masimo Co. (NASDAQ:MASI) to announce sales of $295.72 million for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Masimo’s earnings, with the highest sales estimate coming in at $296.40 million and the lowest estimate coming in at $295.03 million. Masimo reported sales of $278.11 million during the same quarter last year, which would suggest a positive year over year growth rate of 6.3%. The firm is expected to issue its next earnings report on Tuesday, October 26th.

On average, analysts expect that Masimo will report full year sales of $1.22 billion for the current financial year. For the next financial year, analysts anticipate that the firm will report sales of $1.34 billion, with estimates ranging from $1.33 billion to $1.35 billion. Zacks’ sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Masimo.

Masimo (NASDAQ:MASI) last announced its quarterly earnings data on Monday, July 26th. The medical equipment provider reported $0.94 EPS for the quarter, beating the consensus estimate of $0.90 by $0.04. Masimo had a net margin of 19.00% and a return on equity of 15.17%. The business had revenue of $300.78 million during the quarter, compared to analysts’ expectations of $295.60 million. During the same period in the previous year, the business posted $0.85 EPS. The business’s quarterly revenue was down .1% compared to the same quarter last year.

MASI has been the subject of several analyst reports. Piper Sandler boosted their target price on shares of Masimo from $295.00 to $300.00 and gave the company an “overweight” rating in a research note on Wednesday, July 28th. Raymond James initiated coverage on shares of Masimo in a research note on Tuesday. They issued a “market perform” rating for the company. Finally, Zacks Investment Research upgraded shares of Masimo from a “hold” rating to a “buy” rating and set a $298.00 target price for the company in a research note on Monday, September 27th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Buy” and an average target price of $293.80.

A number of large investors have recently bought and sold shares of the business. Koshinski Asset Management Inc. acquired a new position in Masimo during the third quarter worth $134,000. Level Four Advisory Services LLC acquired a new position in Masimo during the third quarter worth $303,000. Windsor Group LTD acquired a new position in Masimo during the third quarter worth $238,000. West Oak Capital LLC raised its position in Masimo by 18.2% during the third quarter. West Oak Capital LLC now owns 325 shares of the medical equipment provider’s stock worth $88,000 after acquiring an additional 50 shares during the period. Finally, Thrivent Financial for Lutherans raised its position in Masimo by 195.2% during the second quarter. Thrivent Financial for Lutherans now owns 40,402 shares of the medical equipment provider’s stock worth $9,796,000 after acquiring an additional 26,716 shares during the period. Institutional investors own 82.24% of the company’s stock.

NASDAQ MASI traded up $7.65 on Wednesday, hitting $278.64. 178,888 shares of the company’s stock traded hands, compared to its average volume of 303,905. Masimo has a 1-year low of $205.10 and a 1-year high of $288.27. The firm’s 50-day moving average price is $274.07 and its two-hundred day moving average price is $250.59. The firm has a market capitalization of $15.34 billion, a PE ratio of 72.19 and a beta of 0.79.

About Masimo

Masimo Corp. is a medical technology company, which develops, manufactures and markets non invasive patient monitoring technologies, medical devices and sensors. Its products include continuous monitors, patient-worn monitors, hospital automation connectivity, capnography & gas, data download & analytics and sensors & accessories.

Further Reading: Understanding dividend yield and dividend payout ratio

Get a free copy of the Zacks research report on Masimo (MASI)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Masimo (NASDAQ:MASI)

Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with's FREE daily email newsletter.